Statistical analysis showed that treatment with Sorafenib alone significantly decreased HCC growth in HLE cells and SK-Hep cells, while co-treatment with 80 ng/ml DCP and Sorafenib significantly decreased the efficacy of Sorafenib in these cells (Figure 2A and Figure 2C, p < 0.05). The gene discussed is ACE; the disease is hepatocellular carcinoma.